Methods and dosage forms with modified viscosity layers

A method for achieving blood plasma concentration levels of a drug in a patient, the method comprising the steps of:

• (a) providing a dosage form comprising a drug layer having a drug therein;
• (b) administering the dosage form to the patient;
• (c) delivering the drug from the dosage form such that no drug is detectable in the plasma for a period of up to three hours from administering the dosage form, and approximately 6 ng/ml to 8 ng/ml of the drug is detectable in the plasma within three to four hours from administering the dosage form, and approximately 8 ng/ml to 12 ng/ml of the drug is detectable in the plasma from about eighteen hours to about twenty hours after administering the dosage form.

A method for achieving plasma concentration levels of a tricyclic amine in a patient, the method comprising the steps of:

• (a) providing a dosage form comprising a drug layer having a tricyclic amine therein;
• (b) administering the dosage form to the patient;
• (c) delivering the tricyclic amine to the patient from the dosage form such that no tricyclic amine is detectable in the plasma for a period of up to three hours from administering the dosage form, and approximately 6 ng/ml to 8 ng/ml of the tricyclic amine is detectable in the plasma within three to four hours from administering the dosage form, and approximately 8 ng/ml to 12 ng/ml of the tricyclic amine is detectable in the plasma from about eighteen hours to about twenty hours after administering the dosage form.

A method for achieving blood plasma concentration levels of a drug in a patient, the method comprising the steps of:

• (a) providing a dosage form comprising a drug layer having a drug therein;
• (b) administering the dosage form to the patient;
• (c) delivering the drug from the dosage form such that no drug is detectable in the plasma for a period of up to three hours from administering the dosage form, and approximately 6.5 ng/ml to 6.9 ng/ml of the drug is detectable in the plasma within three to four hours from administering the dosage form, and approximately 9.7 ng/ml to 10.2 ng/ml of the drug is detectable in the plasma from about eighteen hours to about twenty hours after administering the dosage form.

A method for achieving plasma concentration levels of a tricyclic amine in a patient, the method comprising the steps of:

• (a) providing a dosage form comprising a drug layer having a tricyclic amine therein;
• (b) administering the dosage form to the patient;
• (c) delivering the tricyclic amine to the patient from the dosage form such that no tricyclic amine is detectable in the plasma for a period of up to three hours from administering the dosage form, and approximately 65 ng/ml to 6.9 ng/ml of the tricyclic amine is detectable in the plasma within three to four hours from administering the dosage form, and approximately 9.7 ng/ml to 10.2 ng/ml of the tricyclic amine is detectable in the plasma from about eighteen hours to about twenty hours after administering the dosage form.

A method for treating a condition in a patient, the method comprising the steps of:

• (a) providing a dosage form comprising a tricyclic amine;
• (b) administering the dosage form to the patient;
• (c) delivering the tricyclic amine to the patient from the dosage form such that a modulated, substantially ascending plasma concentration of the tricyclic amine is achieved ranging from about 7 ng/ml to about 11 ng/ml for a period of time from about 16 hours to about 18 hours after administering the dosage form.